The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer ...
The share price of Esperion Therapeutics ESPR lost 54.3% on Mar 16 after management reported a disagreement with one of its partners over certain milestone payments. Last year,Esperion announced that ...
Esperion Therapeutics continues to report lackluster growth with their NEXLETOL and NEXLIZET products. As a result, the share price continues to hit fresh all-time-lows with little-to-no signs of a ...
Esperion Therapeutics (ESPR) has been beaten down lately with too much selling pressure. While the stock has lost 51% over the past four weeks, there is light at the end of the tunnel as it is now in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results